Gastroenterology

Decoding Your Pathology Report and Staging

At a Glance

A chronic atrophic gastritis pathology report should describe biopsies from the antrum, corpus, and incisura. OLGA and OLGIM stages, metaplasia type, H. pylori status, and dysplasia help determine future monitoring.

Your pathology report is an essential tool for managing chronic atrophic gastritis (CAG). The diagnosis of atrophy—the actual loss of gastric glands—cannot be confirmed by sight alone during an endoscopy ^[1]^[2]. It requires a pathologist to examine tissue samples under a microscope.

The Standard for Accuracy: Biopsy Mapping

To get a complete picture of your stomach’s health, your gastroenterologist should follow a specific “mapping” protocol ^[3]. Because atrophic changes can be patchy, taking only one or two biopsies can miss high-risk areas.

A high-quality biopsy protocol generally involves taking at least five samples from specific locations, though sampling sites and jar arrangements can vary by laboratory protocol:

Antrum (2 samples): The lower part of the stomach.
Corpus (2 samples): The main body or upper part of the stomach.
Incisura Angularis (1 sample): The “notch” where the stomach curves.

Including the incisura is critical; research shows that omitting this single biopsy site can miss significant atrophy and may result in an incorrectly low score ^[3]^[4]. These samples are typically sent to the lab separately ^[5].

Staging Your Risk: OLGA and OLGIM

Once the pathologist examines the samples, they use two main risk-stratification systems to score your condition from 0 to IV ^[6].

OLGA (Atrophy): This score measures the overall loss of normal gastric glands ^[7].
OLGIM (Metaplasia): This score measures intestinal metaplasia ^[7].

What the Stages Mean:

Stages 0–I: Generally considered lower-risk. These levels often do not require frequent follow-up endoscopies unless other risk factors are present ^[8]^[9].
Stage II: An intermediate category ^[7].
Stages III–IV: Known as advanced histology. These stages carry a significantly higher risk for future complications compared to stages 0–II ^[9].

Note: Pathology reports may not provide formal staging automatically. If OLGA/OLGIM is absent, you can ask a gastroenterologist or pathologist to calculate the stage from the site-specific pathology rather than assuming the procedure was inadequate.

Complete vs. Incomplete Metaplasia

Your report may also describe the “type” of intestinal metaplasia found, which is a crucial detail for your long-term plan.

Complete Metaplasia: The cells look very much like healthy small intestine cells. This is generally considered a lower-risk form ^[10]^[11].
Incomplete Metaplasia: The cells show a mix of stomach and intestinal features and appear more “disorganized.” This type is associated with a higher risk and may prompt closer monitoring ^[10]^[12].

Pathology Report Checklist

When you review your report, ensure it includes these essential details. If any are missing, you should ask your doctor for clarification.

[ ] H. pylori Status: Was the bacterium found? (Absence of H. pylori on biopsy does not exclude infection) ^[5].
[ ] Specific Locations: Are findings for the antrum, corpus, and incisura noted? ^[8].
[ ] Severity of Atrophy: Is the loss of glands described as mild, moderate, or severe? ^[1].
[ ] Metaplasia Type: Is it identified as “complete” or “incomplete”? ^[10].
[ ] Presence of Dysplasia: This refers to precancerous cell changes. If found, it generally warrants prompt specialist and often expert-pathology review ^[13].

Understanding these terms allows you to move from a place of uncertainty to a place of active management. Your stage is not a destiny; it is a tool used to inform personalized screening ^[14].

Common questions in this guide

What does atrophy mean in chronic atrophic gastritis?

Atrophy means that some of the normal glands in the stomach lining have been lost. It cannot be confirmed reliably by looking during endoscopy; a pathologist must examine biopsy tissue under a microscope.

Why are biopsies taken from several parts of the stomach?

Changes can occur in patches, so one or two samples may miss important areas. A complete mapping approach usually takes at least five biopsies from the antrum, corpus, and incisura, often placing samples from each site in separate containers.

What do OLGA and OLGIM stages mean?

Both systems rate findings from 0 to IV. OLGA measures loss of stomach glands, while OLGIM measures intestinal metaplasia; stages III and IV are considered advanced and generally carry more risk than stages 0 through II.

Is complete or incomplete intestinal metaplasia more concerning?

Incomplete intestinal metaplasia is generally considered higher risk because the cells retain mixed stomach and intestinal features. Complete metaplasia more closely resembles small-intestine cells and is generally lower risk, although overall risk depends on the full pathology and clinical picture.

Can a negative H. pylori biopsy rule out infection?

No. H. pylori may be absent from the biopsy even when infection is present, so a negative biopsy result does not by itself exclude infection. Discuss the result with your clinician, who can decide whether more evaluation is needed.

What should I do if dysplasia is found?

Dysplasia means that cells show precancerous changes. It generally calls for prompt specialist evaluation and often review of the slides by an experienced pathologist, so ask your care team what the result means and what follow-up is needed.

How often will I need another endoscopy?

The interval depends on your OLGA or OLGIM stage, where atrophy is found, whether metaplasia is complete or incomplete, whether dysplasia is present, and other risk factors. Lower-risk stages may not require frequent repeat endoscopies, whereas advanced findings often lead to closer monitoring; your gastroenterologist should set the schedule.

Get notified when new evidence is published on chronic atrophic gastritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (14)

1
AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review.
Shah SC, Piazuelo MB, Kuipers EJ, Li D
Gastroenterology 2021; (161(4)):1325-1332.e7 doi:10.1053/j.gastro.2021.06.078.
PMID: 34454714
2
Diagnosing chronic atrophic gastritis by gastroscopy using artificial intelligence.
Zhang Y, Li F, Yuan F, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2020; (52(5)):566-572 doi:10.1016/j.dld.2019.12.146.
PMID: 32061504
3
Impact of the angulus biopsy for the detection of gastric preneoplastic conditions and gastric cancer risk assessment.
Varbanova M, Wex T, Jechorek D, et al.
Journal of clinical pathology 2016; (69(1)):19-25 doi:10.1136/jclinpath-2015-202858.
PMID: 26163538
4
ROLE OF INCISURA ANGULARIS BIOPSY IN GASTRITIS STAGING AND RISK ASSESSMENT OF GASTRIC CÂNCER.
Ferrari F, Ogata DC, Mello CAL
Arquivos de gastroenterologia 2023; (60(4)):478-489 doi:10.1590/S0004-2803.23042023-120.
PMID: 38018553
5
AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.
Shah SC, Wang AY, Wallace MB, Hwang JH
Gastroenterology 2025; (168(2)):405-416.e1 doi:10.1053/j.gastro.2024.11.001.
PMID: 39718517
6
The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
Wang X, Lu B, Meng L, et al.
Scandinavian journal of gastroenterology 2017; (52(8)):822-827 doi:10.1080/00365521.2017.1315739.
PMID: 28436254
7
Gastric Mucosa Cancer Risk: The Operative Link on Gastritis Assessment Staging System.
Rugge M, Sbaraglia M, Fiorini G, et al.
The Korean journal of helicobacter and upper gastrointestinal research 2026; (26(3)):265-274 doi:10.7704/kjhugr.2026.0027.
PMID: 42754997
8
Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025.
Dinis-Ribeiro M, Libânio D, Uchima H, et al.
Endoscopy 2025; (57(5)):504-554 doi:10.1055/a-2529-5025.
PMID: 40112834
9
OLGA and OLGIM staging systems on the risk assessment of gastric cancer: a systematic review and meta‑analysis of prospective cohorts.
Benites-Goñi H, Cabrera-Hinojosa D, Latorre G, et al.
Therapeutic advances in gastroenterology 2025; (18()):17562848251325461 doi:10.1177/17562848251325461.
PMID: 40104323
10
A meta-analysis and systematic review on subtypes of gastric intestinal metaplasia and neoplasia risk.
Wei N, Zhou M, Lei S, et al.
Cancer cell international 2021; (21(1)):173 doi:10.1186/s12935-021-01869-0.
PMID: 33731114
11
Hybrid identity and distinct methylation profiles of incomplete intestinal metaplasia in the stomach.
Kim H, Kim J, Jeong IH, et al.
Gut 2025; (75(1)):10-23 doi:10.1136/gutjnl-2025-335793.
PMID: 40691053
12
Incomplete Intestinal Metaplasia as a High-Risk Clinical Phenotype in Gastric Carcinogenesis: Implications for Surveillance and Management.
Wei H, Chen W, Chen X, et al.
Digestion 2026; 1-15 doi:10.1159/000553633.
PMID: 42611800
13
Helicobacter pylori-induced inflammation masks the underlying presence of low-grade dysplasia on gastric lesions.
Panarese A, Galatola G, Armentano R, et al.
World journal of gastroenterology 2020; (26(26)):3834-3850 doi:10.3748/wjg.v26.i26.3834.
PMID: 32774061
14
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).
Lee JWJ, Zhu F, Srivastava S, et al.
Gut 2022; (71(5)):854-863 doi:10.1136/gutjnl-2021-324057.
PMID: 33975867

This page is for informational purposes only and does not constitute medical advice. Your gastroenterologist and pathologist should interpret your chronic atrophic gastritis report and recommend follow-up for your specific situation.

Guide Contents